These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 6357429

  • 1. Ovarian reticular cell sarcoma of the mouse (M5076) made resistant to cyclophosphamide.
    D'Incalci M, Torti L, Damia G, Erba E, Morasca L, Garattini S.
    Cancer Res; 1983 Dec; 43(12 Pt 1):5674-80. PubMed ID: 6357429
    [Abstract] [Full Text] [Related]

  • 2. Characterization of a novel mouse reticular cell sarcoma M5076 subline resistant to cisplatin.
    Ferrari A, Damia G, Erba E, Rossi C, Mandelli R, D'Incalci M.
    Int J Cancer; 1989 Jun 15; 43(6):1091-7. PubMed ID: 2659542
    [Abstract] [Full Text] [Related]

  • 3. Response of drug-sensitive and -resistant L1210 leukemias to high-dose chemotherapy.
    Griswold DP, Trader MW, Frei E, Peters WP, Wolpert MK, Laster WR.
    Cancer Res; 1987 May 01; 47(9):2323-7. PubMed ID: 3567926
    [Abstract] [Full Text] [Related]

  • 4. The role of drug transport in resistance to nitrogen mustard and other alkylating agents in L518Y lymphoblsts.
    Goldenberg GJ.
    Cancer Res; 1975 Jul 01; 35(7):1687-92. PubMed ID: 1055634
    [Abstract] [Full Text] [Related]

  • 5. Activity of 1-p-(3,3-dimethyl-1-triazeno) benzoic acid potassium salt in M 5076/73A ovarian reticular cell sarcoma of the mouse.
    Colombo T, Garattini S, Lassiani L, D'Incalci M.
    Cancer Treat Rep; 1982 Nov 01; 66(11):1945-8. PubMed ID: 6754075
    [Abstract] [Full Text] [Related]

  • 6. Preclinical studies and clinical correlation of the effect of alkylating dose.
    Frei E, Teicher BA, Holden SA, Cathcart KN, Wang YY.
    Cancer Res; 1988 Nov 15; 48(22):6417-23. PubMed ID: 3180059
    [Abstract] [Full Text] [Related]

  • 7. Antitumor activity of 1,4-bis (2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] heptane dimaleate (Dabis Maleate) in M5076 and its subline resistant to cyclophosphamide M5/CTX.
    Tagliabue G, Filippeschi S, Hendricks H, D'Incalci M.
    Ann Oncol; 1992 Mar 15; 3(3):233-6. PubMed ID: 1586622
    [Abstract] [Full Text] [Related]

  • 8. Development and characterization of a cyclophosphamide-resistant mouse plasmacytoma cell line.
    Frondoza CG, Trivedi SM, Humphrey RL.
    Cancer Treat Rep; 1982 Jul 15; 66(7):1535-44. PubMed ID: 7093969
    [Abstract] [Full Text] [Related]

  • 9. Antitumoral activity of the oxazaphosphorine derivative, mafosfamide-cyclohexylamine salt (ASTA 7557) on a murine ovarian reticular cell sarcoma and its subline resistant to cyclophosphamide.
    Colombo T, Paolini A, Finazzi M, Scanziani E, Mandelli G, Donelli MG.
    Tumori; 1986 Dec 31; 72(6):637-42. PubMed ID: 3544404
    [Abstract] [Full Text] [Related]

  • 10. [Effect of Ganoderma lucidum polysaccharides on tumor cell nucleotide content and cell cycle in S180 ascitic tumor-bearing mice].
    Li JJ, Lei LS, Yu CL, Zhu ZG, Zhang Q, Wu SG.
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jul 31; 27(7):1003-5. PubMed ID: 17666337
    [Abstract] [Full Text] [Related]

  • 11. Acute in vivo resistance in high-dose therapy.
    Teicher BA, Ara G, Keyes SR, Herbst RS, Frei E.
    Clin Cancer Res; 1998 Feb 31; 4(2):483-91. PubMed ID: 9516940
    [Abstract] [Full Text] [Related]

  • 12. Resistance patterns of Walker carcinosarcoma 256 and other rodent tumors to cyclophosphamide and L-phenylalanine mustard.
    Schmid FA, Otter GM, Stock CC.
    Cancer Res; 1980 Mar 31; 40(3):830-3. PubMed ID: 7471099
    [Abstract] [Full Text] [Related]

  • 13. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI, Boxall FE, Goddard PM, Valenti M, Jones M, Murrer BA, Abrams M, Kelland LR.
    Clin Cancer Res; 1997 Nov 31; 3(11):2063-74. PubMed ID: 9815598
    [Abstract] [Full Text] [Related]

  • 14. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.
    Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, Bohlen P, Hicklin DJ, Bergers G, Kerbel RS.
    Cancer Res; 2002 May 15; 62(10):2731-5. PubMed ID: 12019144
    [Abstract] [Full Text] [Related]

  • 15. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
    Mohammad RM, Wall NR, Dutcher JA, Al-Katib AM.
    Clin Cancer Res; 2000 Dec 15; 6(12):4950-6. PubMed ID: 11156256
    [Abstract] [Full Text] [Related]

  • 16. Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan.
    Friedman HS, Dolan ME, Kaufmann SH, Colvin OM, Griffith OW, Moschel RC, Schold SC, Bigner DD, Ali-Osman F.
    Cancer Res; 1994 Jul 01; 54(13):3487-93. PubMed ID: 8012971
    [Abstract] [Full Text] [Related]

  • 17. Experimental antitumor activity against murine tumor model systems of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one (mitozolomide), a novel broad-spectrum agent.
    Hickman JA, Stevens MF, Gibson NW, Langdon SP, Fizames C, Lavelle F, Atassi G, Lunt E, Tilson RM.
    Cancer Res; 1985 Jul 01; 45(7):3008-13. PubMed ID: 4005840
    [Abstract] [Full Text] [Related]

  • 18. Rapid development of drug resistance in human ovarian tumor xenografts after a single treatment with melphalan in Vivo.
    Caffrey PB, Zhang Y, Frenkel GD.
    Anticancer Res; 1998 Jul 01; 18(4C):3021-5. PubMed ID: 9713503
    [Abstract] [Full Text] [Related]

  • 19. Antitumor activity of the novel nitrosourea S10036 in rodent tumors.
    Filippeschi S, Colombo T, Bassani D, De Francesco L, Arioli P, D'Incalci M, Bartosek I, Guaitani A.
    Anticancer Res; 1988 Jul 01; 8(6):1351-4. PubMed ID: 3064716
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of a "nude" mouse-human tumor panel as a predictive secondary screen for cancer chemotherapeutic agents.
    Bellet RE, Danna V, Mastrangelo MJ, Berd D.
    J Natl Cancer Inst; 1979 Nov 01; 63(5):1185-8. PubMed ID: 91697
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.